Explore chapters and articles related to this topic
The Twentieth Century and Beyond
Published in Scott M. Jackson, Skin Disease and the History of Dermatology, 2023
Nearly all of these contributors are giants in the history of dermatology, and many of them have been honored with eponyms for the diagnoses they first described. Dermatologists are fond of eponyms, but it is always a little difficult to decide whether to tell a patient he has “Grover's disease” or “transient acantholytic dermatosis.”
Skin diseases of the elderly
Published in Robert A. Norman, Geriatric Dermatology, 2020
Transient acantholytic dermatosis7 (Graver’s disease) (Figure 13) is common in men over 40 years of age; its cause is unknown. It can be persistent. Clinically there are scattered pruritic erythematous papules or papulovesicles with crusting on the neck, upper chest, back and trunk. Histologically there are acantholysis and dyskeratosis.
Photoexacerbated Dermatoses
Published in Henry W. Lim, Nicholas A. Soter, Clinical Photomedicine, 2018
Transient acantholytic dermatosis is a disease of middle-aged and elderly men in whom discrete, pruritic, edematous papules or papulovesicles appear, most frequently on the chest and back. Histopathologic features consist of acantholysis with or without dyskeratosis. The original description included six patients, three of whom first developed lesions in sun-exposed areas after intense sun exposure. However, since a fourth patient developed lesions at the site of a contact dermatitis, Grover suggested that the disease was subject to the Koebner phenomenon and not due to photosensitivity per se (83).
Common and uncommon adverse cutaneous reactions to erlotinib: a study of 20 Chinese patients with cancer
Published in Cutaneous and Ocular Toxicology, 2018
Huiling Zhu, Zhe Zhu, Weining Huang, Xiping Cheng, Jiaxi He, Chunping Xiong, Jiande Han
Erlotinib is an orally administered EGFR-TKI. It is a targeted agent commonly used for treating advanced NSCLC (stage IIIB and IV)1. It is often associated with a peculiar spectrum of skin reactions, including acneiform rash, nail changes, regulatory changes in hair and xerosis. Other reactions include telangiectasia, hyperpigmentation, enhancement of radiation dermatitis, oral aphthous ulcers, vasculitis, necrolytic migratory erythema and transient acantholytic dermatosis3,7,8. Acneiform rash is the most common adverse cutaneous reaction3. The other types of adverse cutaneous reactions are rare. This study reported acneiform rash consisting of most alterations of skin disorders; the other adverse cutaneous reactions such as xerosis and nail and hair changes were not infrequent. It was interesting that anaphylactic cutaneous reactions were observed in six out of 20 cases, and this clinical presentation was hitherto not described except for some lesions reported by Toshiyuki Yamamoto9. In 2013, he reported erlotinib-induced seborrheic dermatitis-like eruption on the face and trunk, superficial erosive lesions on the buttock or genital regions, erythema exclusively involving the umbilicus and prurigo nodules on the buttocks in Japan9. A parallel point existed in morphology between only one case of anaphylactic dermatitis presenting as erosive and scaly erythema (Figure 4) and seborrheic dermatitis-like eruption or superficial erosive erythema9. Other cases of anaphylactic dermatitis were different morphologically from those previously described9. The rash presenting like angioneurotic oedema with severe oral mucosal erosion and a high fever in one of the patients (Figure 1) had never been mentioned earlier. Red macules, papules, plaques and brown pigmentation on the whole body other than localized distribution (Figure 5) were characteristic and distinct morphologically compared with the lesions described as prurigo nodules. Moreover, clinical details in the present study indicated anaphylactic cutaneous reaction, including a high percentage of eosinophils in the peripheral blood, eosinophilic infiltration in the dermis layer and good response to antihistamines and topical steroids, which were absent in the literature. The anaphylactic cutaneous reaction has been reported only in Japan and China hitherto. The speculation regarding its susceptibility in Asian population needs to be confirmed by conducting further studies.